Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Scangos Leaves Biogen Transformed And Transitioning

Executive Summary

CEO George Scangos built Biogen into an innovative biotech, but his departure, coming as the company dusts itself off after a fall from glory, increased speculation Biogen could become a takeout target.


Related Content

Biogen CEO Pick Vounatsos Suggests A Return To Commercial Focus
2016 Pharma Dealmaking: Waiting On The High-Value Deals
CEOs In Transition: Internal The Norm, But External Delivers Strong Returns
Merck, Allergan Suggested As Suitors But Biogen's Attractiveness Under Question
Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO
Stockwatch: Earnings Season Appears Not At Home To Brexit
Biogen Anti-LINGO MS Study Failure Removes Upside
Biogen Sets A High R&D Bar With A Pipeline That Extends Well Beyond MS
Belt-Tightening Biogen Looks To Narrow Therapeutic Focus
Biogen Makes Counterintuitive Move To Tap Exelixis's Scangos As CEO


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts